Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease
The University of Texas Medical Branch, Galveston
490 participants
Aug 26, 2025
INTERVENTIONAL
Conditions
Summary
The purpose of the study is to determine which combination of neuromuscular blocking agent and reversal agent is safer to use during anesthesia for patients with chronic kidney disease. The main question it aims to answer is "The use of Cisatracurium with neostigmine leads to less post-operative pulmonary complications than Rocuronium with sugammadex."
Eligibility
Inclusion Criteria4
- The subject is able and willing to provide and sign informed consent
- The subject must be between 18 and 80 years of age
- The subject should have chronic kidney disease as defined by glomerular filtration rate
- The surgery must require general anesthesia with endotracheal intubation and neuromuscular blockade
Exclusion Criteria10
- Any patient under the age of 18
- Any patient over the age of 80
- Any patient with end stage renal disease
- Any patient requiring dialysis
- Patients presenting for Renal Transplantation
- Pregnant Female
- Any patient in the correctional system
- Urgent or Emergent procedure
- The surgery requires intubation post-operatively
- Documented allergy to Rocuronium, Sugammadex, Cisatracurium or Neostigmine
Interventions
Will be assessing neuromuscular blockade with rocuronium and reversal with sugammadex
Will be assessing neuromuscular blockade with neostigmine and reversal with neostigmine
Will be assessing neuromuscular blockade with rocuronium and reversal with sugammadex
Will be assessing neuromuscular blockade with neostigmine and reversal with neostigmine
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07203287